Skip to content

Study · In vitro (cells) · mouse · 2009

9 results

Proliferative and anti-proliferative effects of thymosin alpha1 on cells are associated with manipulation of cellular ROS levels.

Qin Y, Chen FD, Zhou L, Gong XG, Han QF

Chemico-biological interactions12 May 2009Cited by 17 (Europe PMC)

PMID19442654 (opens in a new tab)DOI10.1016/j.cbi.2009.05.006 (opens in a new tab)PepBankPUB-19442654
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Mechanism

    In mouse spleen leukomonocytes, Talpha1 treatment raised the ROS level.

    In plain wordsIn cells from mouse spleens, thymosin alpha1 raised reactive oxygen species levels.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseROS level in leukomonocytes
    Study

    mousen: not reported in source

    leukomonocytes isolated from mouse spleens
    Outcome group
    Oxidative stress · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    the Talpha1-treated leukomonocytes, which were isolated from mice spleens, exhibited a higher ROS level and a lower reduced glutathione (GSH) level
  2. 02LabIn vitro (cells)Mechanism

    In mouse spleen leukomonocytes, Talpha1 treatment lowered the reduced glutathione level.

    In plain wordsIn cells from mouse spleens, thymosin alpha1 lowered the antioxidant glutathione.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseReduced glutathione (GSH) level in leukomonocytes
    Study

    mousen: not reported in source

    leukomonocytes isolated from mouse spleens
    Outcome group
    Oxidative stress · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    the Talpha1-treated leukomonocytes, which were isolated from mice spleens, exhibited a higher ROS level and a lower reduced glutathione (GSH) level
  3. 03LabIn vitro (cells)Mechanism

    In HepG2 hepatoma cells, Talpha1 treatment lowered the ROS level.

    In plain wordsIn human liver cancer cells, thymosin alpha1 lowered reactive oxygen species levels.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseROS level in HepG2 cells
    Study

    humann: not reported in source

    HepG2 human hepatoma cells
    Outcome group
    Oxidative stress · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    HepG2 cells treated with Talpha1 exhibited lower ROS level and higher GSH level.
  4. 04LabIn vitro (cells)Mechanism

    In HepG2 hepatoma cells, Talpha1 treatment raised the GSH level.

    In plain wordsIn human liver cancer cells, thymosin alpha1 raised the antioxidant glutathione.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseGSH level in HepG2 cells
    Study

    humann: not reported in source

    HepG2 human hepatoma cells
    Outcome group
    Oxidative stress · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    HepG2 cells treated with Talpha1 exhibited lower ROS level and higher GSH level.
  5. 05LabIn vitro (cells)Mechanism

    In mouse spleen leukomonocytes, Talpha1 increased the population in the G2 phase of the cell cycle.

    In plain wordsIn cells from mouse spleens, thymosin alpha1 increased the share of cells in the G2 phase of cell division.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseG2 phase population of leukomonocytes
    Study

    mousen: not reported in source

    leukomonocytes isolated from mouse spleens
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In addition, after treatment with Talpha1, the population of leukomonocytes in the G(2) phase increased, resulting in a slight increase in viability.
  6. 06LabIn vitro (cells)Mechanism

    In mouse spleen leukomonocytes, Talpha1 gave a slight increase in viability.

    In plain wordsIn cells from mouse spleens, thymosin alpha1 slightly increased cell survival.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseViability of leukomonocytes
    Study

    mousen: not reported in source

    leukomonocytes isolated from mouse spleens
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In addition, after treatment with Talpha1, the population of leukomonocytes in the G(2) phase increased, resulting in a slight increase in viability.
  7. 07LabIn vitro (cells)Mechanism

    In HepG2 hepatoma cells, Talpha1 delayed the cell cycle in the G1 phase.

    In plain wordsIn human liver cancer cells, thymosin alpha1 delayed progress through the cell cycle.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseG1 phase cell cycle delay in HepG2 cells
    Study

    humann: not reported in source

    HepG2 human hepatoma cells
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    in Talpha1-treated HepG2 cells, the cell cycle was delayed in the G(1) phase
  8. 08LabIn vitro (cells)Mechanism

    In HepG2 hepatoma cells, Talpha1 inhibited tumor cell proliferation.

    In plain wordsIn human liver cancer cells, thymosin alpha1 slowed cell growth.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseProliferation of HepG2 tumor cells
    Study

    humann: not reported in source

    HepG2 human hepatoma cells
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    in Talpha1-treated HepG2 cells, the cell cycle was delayed in the G(1) phase, thereby inhibiting tumor cell proliferation
  9. 09LabIn vitro (cells)Mechanism

    In HepG2 hepatoma cells, Talpha1 treatment dephosphorylated the kinase Akt.

    In plain wordsIn human liver cancer cells, thymosin alpha1 reduced the activation of the signalling protein Akt.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseAkt phosphorylation in HepG2 cells
    Study

    humann: not reported in source

    HepG2 human hepatoma cells
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    dephosphorylation of the serine/threonine kinase Akt was detected.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.